Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) and Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.
Analyst Ratings
This is a summary of current recommendations and price targets for Eloxx Pharmaceuticals and Cyclo Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Eloxx Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
Cyclo Therapeutics | 0 | 2 | 1 | 0 | 2.33 |
Cyclo Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 31.94%. Given Cyclo Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cyclo Therapeutics is more favorable than Eloxx Pharmaceuticals.
Volatility and Risk
Earnings and Valuation
This table compares Eloxx Pharmaceuticals and Cyclo Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Eloxx Pharmaceuticals | N/A | N/A | -$36.06 million | ($9.07) | N/A |
Cyclo Therapeutics | $1.08 million | 19.13 | -$20.06 million | ($0.90) | -0.80 |
Cyclo Therapeutics has higher revenue and earnings than Eloxx Pharmaceuticals. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Eloxx Pharmaceuticals and Cyclo Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Eloxx Pharmaceuticals | N/A | N/A | N/A |
Cyclo Therapeutics | -2,847.19% | -28,686.89% | -278.54% |
Institutional and Insider Ownership
2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Cyclo Therapeutics beats Eloxx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.